AF
NVO

Align Financial’s Novo Nordisk NVO Stock Holding History

Align Financial’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.9K Hold
812
– – 0.02% 177
2026
Q1 		$29.8K Sell
812
-40,503
-98% -$1.92M 0.02% 191
2025
Q4 		$41.3K Buy
+41,315
New +$2.11M 0.02% 170

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Align Financial's NVO Position: Q2 2026 in Review

Align Financial held its Novo Nordisk (NVO) position steady in Q2 2026 at 812 shares worth $38.9K. The position accounts for 0.02% of the portfolio, ranked #177.

Align Financial first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $41.3K in Q4 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Align Financial held 812 shares of Novo Nordisk worth $38.9K as of Q2 2026.
  • Align Financial left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.02% of Align Financial's portfolio in Q2 2026, its #177 holding.
  • Align Financial first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • Align Financial's Novo Nordisk position peaked at $41.3K in Q4 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Align Financial's 13F filing for Q2 2026, filed 27 Jul 2026.